Table 1.
Characteristics of All Patients With Human Coronavirus Lower Respiratory Tract Disease
| Characteristic | Total (N = 35) | Hematopoietic Cell Transplant Recipients (n = 28) | Patients With Hematologic Malignancy (n = 7) |
|---|---|---|---|
| Female sex | 10 (29) | 10 (36) | 0 |
| Age, y, median (range) | 53 (8–68) | 53.5 (24–67) | 52 (8–68) |
| Underlying pulmonary disordera | 10 (29) | 10 (36) | 0 |
| Immunosuppressive therapy or chemotherapy | 34 (97) | 27 (96) | 7 (100) |
| Transplant year | |||
| 1996–2006 |
6 (21) | ||
| 2007–2015 |
22 (79) | ||
| Transplant number ≥2 | 10 (36) | ||
| Cell source | |||
| Cord | 1 (11) | ||
| Bone marrow | 6 (21) | ||
| PBSC | 21 (75) | ||
| Donor type | |||
| Autologous | 4 (14) | ||
| Related | 10 (36) | ||
| Unrelated | 14 (50) | ||
| Days between transplant and HCoV LRTD, median (range) | 302 (8–7045) | ||
Data are presented as No. (11) unless otherwise indicated.
Abbreviations: HCoV, human coronavirus; LRTD, lower respiratory tract disease; PBSC, peripheral blood stem cell.
a Bronchiolitis obliterans (n = 4), lung transplantation for bronchiolitis obliterans (n = 1), lung transplantation for cystic fibrosis (n = 1), radiation pneumonia (n = 2), asthma (n = 1), prolonged acute respiratory distress syndrome (n = 1), diffuse alveolar hemorrhage (n = 1), cystic fibrosis (n = 1).